Trial Profile
A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-response Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 02 Jan 2024
Price :
$35
*
At a glance
- Drugs Cenerimod (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Actelion Pharmaceuticals; Idorsia Pharmaceuticals
- 15 Nov 2023 Results assessing the leukocytes, autoantibodies, and inflammation biomarkers of once-daily cenerimod (0.5, 1, 2, or 4 mg) versus placebo in patients with SLE from NCT02472795 and NCT03742037 trials, presented at the ACR Convergence 2023.
- 06 Jun 2020 Results assessing preclinical and clinical characterization of cenerimod in systemic lupus erythematosus, presented at the 21st Annual Congress of the European League Against Rheumatism.
- 02 Oct 2019 According to an Idorsia Pharmaceuticals media release, data from this study ill be shared during the American College of Rheumatology (ACR) / Association for Rheumatology Professionals (ARP) Annual Meeting 2019 (Atlanta, Georgia, US).